55 PROMs in autosomal inherited bleeding disorders: A systematic literature review 2 the years from the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Dutch ‘Innovatiefonds Zorgverzekeraars’, Pfizer, Baxter/Baxalta/Shire, Bayer Schering Pharma, CSL Behring, Sobi, Novo Nordisk, Novartis and Nordic Pharma and has served as a steering board member for Roche and Bayer. All grants, awards and fees go to the institution. The other authors declare no conflicts of interest relevant to the contents of this manuscript. Funding This study was performed on behalf of the SYMPHONY consortium (NWA.1160.18.038.) which is funded by a grant from the Netherlands Organization for Scientific Research (NWO). Acknowledgements The authors wish to thank Dr. M.F.M. Engel from the Erasmus MC Medical Library for developing and updating the search strategies. The SYMPHONY consortium, which aims to orchestrate personalized treatment in patients with bleeding disorders, is a unique collaboration between patients, health care professionals and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. SYMPHONY aims to identify best treatment choice for each individual based on bleeding phenotype. In order to achieve this goal, workpackages have been organized according to three themes e.g. Diagnostics (workpackage 3&4), Treatment (workpackages 5-9) and Fundamental Research (workpackages 10-12). This research received funding from the Netherlands Organization for Scientific Research (NWO) in the framework of the NWA-ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr. M.H. Cnossen. Project manager: Dr. S.H. Reitsma. More information: www.symphonyconsortium.nl. Beneficiaries of the SYMPHONY consortium: Erasmus MC – Sophia Children’s Hospital, University Medical Center Rotterdam, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., Swedish Orphan Biovitrum (Belgium) BVBA/SPRL.
RkJQdWJsaXNoZXIy MTk4NDMw